Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.34 |
| ▸ | TLR4 | O00206 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26762028 | 0.86 | PDE4D (0.43) | PDE4DPDE4BTLR8TLR7TLR9 | |
| SCHEMBL23717464 | 0.84 | ALK (0.32) | — | |
| SCHEMBL24447954 | 0.82 | PDE4D (0.36) | PDE4DPDE4BTLR8TLR7TLR9 | |
| SCHEMBL26762009 | 0.78 | TLR8 (0.37) | PDE4DPDE4BTLR8TLR7TLR9 | |
| SCHEMBL26762008 | 0.78 | TLR8 (0.42) | PDE4DPDE4BTLR8TLR7TLR9 | |
| SCHEMBL23674887 | 0.75 | KMT2A (0.37) | PDE4DPDE4BTLR8TLR7TLR9 | |
| SCHEMBL24345422 | 0.70 | HRH1 (0.44) | KCNH2 | |
| SCHEMBL26762030 | 0.69 | KMO (0.32) | — | |
| SCHEMBL26762032 | 0.69 | CRHR1 (0.33) | — | |
| SCHEMBL26482524 | 0.69 | TLR8 (0.44) | TLR8IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | PDE4D 1685/4885PDE4B 689/4885TLR8 897/4885 |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | PDE4D 2076/4885PDE4B 788/4885TLR8 1278/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | PDE4D 2462/4885PDE4B 934/4885TLR8 1501/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | PDE4D 1685/4885PDE4B 689/4885TLR8 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.